Search: onr:"swepub:oai:gup.ub.gu.se/135484" >
Effects of the micr...
Effects of the microsomal triglyceride transfer protein (MTP) inhibitor JNJ-16269110 on glycemic control and body weight in subjects with type 2 diabetes mellitus (T2DM) on metformin
-
- Stenlöf, Kaj, 1965 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för klinisk prövning och entreprenörskap,Institute of Medicine, Department of Clinical Trials and Entrepreneurship
-
Wajs, E (author)
-
Vercruysse, F (author)
-
show more...
-
Ways, D (author)
-
Ouwerkerk-Mahadevan, S (author)
-
Penson, J (author)
-
Van Nueten, L (author)
-
show less...
-
(creator_code:org_t)
- 2010
- 2010
- English.
-
In: Obesity Reviews (Poster presentations). - 1467-7881. ; 11:Supplement s1
- Related links:
-
https://gup.ub.gu.se...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Introduction: JNJ-16269110 is a novel enterocyte-targeted MTP inhibitor acting via enterically-mediated hormonal and neural mechanisms being investigated for treatment of obesity. Methods: Three hundred and fifty two subjects with T2DM (BMI 32.8 kg/m2; 54% males) were randomized to placebo, JNJ-16269110 5-mg bid, 10-mg bid or 15-mg bid for 12 weeks in a double-blind multicenter clinical trial to assess safety and efficacy of this agent. The primary efficacy endpoint was change from baseline to Week 12 in HbA1c (ITT-mixed-model). Secondary endpoints included changes in fasting plasma glucose (FPG), body weight (BW), and plasma lipids. Results: Gastrointestinal symptoms were the most common reason for early discontinuation in the JNJ-16269110 arms (2%, 12%, 9% of subjects in 5-mg, 10-mg, 15-mg bid groups, respectively, vs. 1% in placebo group). Conclusion: Compared to placebo, JNJ-16269110 10-mg and 15-mg bid improved glycemic control and reduced BW. The most common side effects were related to the astrointestinal system. Conflict of interest: K. Stenlof received funding from Johnson and Johnson as principal investigator and consultant. E. Wajs, F. Vercruysse, D. Ways, S. Ouwerkerk-Mahadevan, J. Penson, and L. Van Nueten are employees and shareholders of Johnson and Johnson. Funding: The study was funded by Johnson & Johnson Pharmaceutical Research and Development.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Publication and Content Type
- ref (subject category)
- kon (subject category)
Find in a library
To the university's database